The number of biopharma and biotech companies developing and launching new therapies is continuing to rise with emerging biopharma remaining a strong source of innovation. At the same time, more barriers to success are emerging with requirements for increasingly complex clinical trials, continuous regulatory changes, evolving payer conditions, and more restrictive access to HCPs.
It’s evident that asset success starts early, with a need to ensure evidence generation delivers endpoints that demonstrate value to regulators, payers, prescribers, and patients. Communicating that value requires an adaptable, omnichannel approach to activate and engage all stakeholders for launch and throughout the product lifecycle.
Learn how IQVIA is helping clinical and commercial customers bring therapies to market and to the patients who need them.
IQVIA experts will break down the components of successful commercialization for emerging biopharma and biotech companies.
Asset Success Starts Early: Demonstrating and Communicating the Value of Your Therapy
IQVIA experts will share perspectives on how emerging biopharma companies can demonstrate and communicate the value of new therapies by engaging thought leaders to ensure their innovation reaches the patients who need it.
Ask the experts
IQVIA experts will take your questions at the end of each session. If they are unable to address every question live, they will follow up with an answer individually to ensure you have the information you need.